Krónikus limfoid leukémia (CLL): vizsgálatok itt: Hollandia
13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Almere, Arnhem, Dordrecht, Hilversum
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - 2. fázisNot yet taking people in HollandiaAddition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma
- Where
- Almelo, Amersfoort, Amstelveen, Amsterdam, Apeldoorn, Breda, Doetichem, Emmen, Goes, Gouda, Groningen, Hoofddorp, Hoorn Nh, Leeuwarden, Nieuwegein, Rotterdam, 's-Gravenhage, 'S-Hertogenbosch, Tilburg, Venlo, Zaandam, Zwolle
- Életkor
- 18 év and over
- People
- 177
- Run by
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2026-526101-15-00 · EU 2026-526101-15-00 - 1/2. fázisTaking peopleSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Utrecht
- Életkor
- 1 év to 17 év
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00 - 2. fázisNot yet taking people in HollandiaTreatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.
- Where
- Amersfoort, Amsterdam, Breda, Doetinchem, Dordrecht, Eindhoven, Groningen, Hoofddorp, Leeuwarden, Nieuwegein, Rotterdam, 'S-Gravenhage
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07860775 · EU 2025-524842-89-00 - 1/2. fázisTaking peopleVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
- Where
- Alkmaar, Amersfoort, Amsterdam, Dordrecht, Ede Gld, Eindhoven, Groningen, Leeuwarden, 's-Gravenhage, 's-Hertogenbosch, Tilburg, Utrecht
- Életkor
- 18 év and over
- People
- 112 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT05791409 · EU 2022-500305-40-00 - 3. fázisTaking peopleA phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
- Where
- Arnhem, Ede Gld, Geleen, Harderwijk, Leeuwarden, Leiderdorp, Nijmegen, 'S-Hertogenbosch, Tiel, Zwolle
- Életkor
- 18 év and over
- People
- 746 worldwide
- Run by
- University Of Cologne
See details and how to join2023-510294-34-00 · EU 2023-510294-34-00 - 3. fázisTaking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Dordrecht, Eindhoven, Gouda, Groningen, Nijmegen, Utrecht
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - 3. fázisTaking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Almere, Dordrecht, 's-Gravenhage
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - 2. fázisTaking peopleREtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
- Where
- Amsterdam, Arnhem, Breda, Delft, Dordrecht, Ede Gld, Eindhoven, Gouda, Groningen, Leeuwarden, Maastricht, Nieuwegein, Rotterdam, 's-Hertogenbosch, Terneuzen, Utrecht
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT04523428 · EU 2023-505449-18-00 - 3. fázisTaking peopleA long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Where
- Amsterdam, Leiden, Maastricht, Rotterdam
- Életkor
- 18 év and over
- People
- 309 worldwide
- Run by
- Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00 - 3. fázisTaking peopleHO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment
- Where
- Alkmaar, Amstelveen, Arnhem, Beugen, Beverwijk, Breda, Delft, Deventer, Dirksland, Doetinchem, Dordrecht, Ede Gld, Emmen, Enschede, Geldrop, Geleen, Gorinchem, Gouda, Groningen, Harderwijk, Heerenveen, Helmond, Hoofddorp, Leeuwarden, Nieuwegein, Roermond, Roosendaal, Rotterdam, 's-Gravenhage, 'S-Hertogenbosch, Terneuzen, Tiel, Tilburg, Uden, Utrecht, Zaandam, Zwolle
- Életkor
- 18 év and over
- People
- 456
- Run by
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2025-524283-38-00 · EU 2025-524283-38-00 - 1. fázisTaking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Groningen, Nijmegen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00